Navigation Links
Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
Date:9/22/2008

MONTREAL, Sept. 22 /PRNewswire/ -- Enobia Pharma, a biotech company focused on developing novel therapeutics for serious bone disorders, today announced key appointments to add commercial and manufacturing expertise to the Company's senior management team in conjunction with the recent initiation of two clinical trials of ENB-0040 for the treatment of hypophosphatasia.

Julie Anne Smith has been appointed as Enobia's Vice President, Chief Commercial Officer, and Jayant Aphale, PhD., MBA has been appointed as Vice President, Manufacturing and Process Sciences. Prior to joining Enobia, Ms. Smith was Vice President, Commercial at Jazz Pharmaceuticals Inc. where she led commercial strategy and operations. Previously, Ms. Smith was Vice President, Global Marketing for Genzyme and led the Global Marketing department for Genzyme's rare disease therapeutics business division. Her responsibilities included leading the worldwide commercialization and planning for Myozyme(R), an enzyme replacement therapy for ultra-orphan Pompe disease.

Dr. Aphale was the former Vice President Operations and Project/Portfolio Management at Acambis plc. At Acambis, Dr. Aphale was responsible for R&D project management as well overseeing multiple vaccine manufacturing plants, which included cGMP upstream and downstream manufacturing, and a lyophilization facility. Dr. Aphale previously held Director level positions at Wyeth Vaccines and Diosynth Biotechnology, a biologics contract manufacturing organization. Prior to that, Dr. Aphale was a senior scientist, cGMP manufacturing at Roche Molecular Systems where he was responsible for technology transfer and manufacturing and release of heat stable enzymes.

"Julie and Jayant are seasoned executives who bring to Enobia extensive industry experience that will be extremely valuable as we continue to progress our clinical program for hypophosphatasia and to prepare our commercial efforts," stated Robert Heft, PhD., Chief Execu
'/>"/>

SOURCE Enobia Pharma
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
2. Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
3. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
4. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
5. Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program
6. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
7. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
8. VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
9. Unibioscreen and Drais Pharmaceuticals Partner to Develop and Commercialize UNBS 5162 for Treatment of Cancer
10. Vanda Pharmaceuticals Provides Update on Iloperidone
11. Cerimon Pharmaceuticals Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... 16 RealMed has been ranked ... the 2009 Top 20 Best in ... report. RealMed is a dynamic revenue cycle ... processing between healthcare providers and all ... firm specializing in vendor performance measurement in ...
(Date:12/16/2009)... to Millennium Research Group (MRG), the global authority ... in China supported rapid expansion of the Chinese ... to fuel growth in the coming years. ... Cardiology Devices 2010 report finds that initiatives ... Chinese drug-eluting stent market to reach a value ...
(Date:12/16/2009)... -- Biovista Inc.,today announced that it was awarded ... the 2009 New England Venture Summit, held on ... cutting edge private companies,driving the future of innovation, ... other privately held companies that play a leading ... Clean-tech sectors. , "We ...
Breaking Medicine Technology:RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 2Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 3Biovista Inc. Named Top Innovator in Life Sciences 2Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU 016 55596 1Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU 016 55596 2Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU 016 55596 3Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU 016 55596 4Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU 016 55596 5Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU 016 55596 6Fast Food Choices for iPhone 28TM 29 iPod 28R 29 Touch Users With Celiac Coeliac 26 Food Allergies 55593 1Fast Food Choices for iPhone 28TM 29 iPod 28R 29 Touch Users With Celiac Coeliac 26 Food Allergies 55593 2Haven Healthcare of Utah Receives Award for Quality Care Fourth Year in a Row 55588 1Haven Healthcare of Utah Receives Award for Quality Care Fourth Year in a Row 55588 2
... ... Annually, CAMBRIDGE, Mass., Aug. 2 ... trial of Mozobil(TM),(plerixafor) has successfully met its primary and secondary endpoints,demonstrating positive ... non-Hodgkin,s lymphoma. The combined strength of these two trials -- in ...
... KING OF PRUSSIA, Pa., Aug. 2 ... experiments with its small-molecule,MIF inhibitors showed oral ... the Company announced that it is advancing ... Macrophage Migration Inhibitory Factor, or MIF, is ...
Other Medicine Technology:Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint 2Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint 3Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint 4Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint 5Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint 6Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint 7Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors 2
(Date:12/17/2009)... last few weeks there has been an increase of ... e cigarette opposition in an attempt to scare the ... tactics of these groups when the evidence clearly shows ... tobacco according to several studies, lab reports and opinions ... world. ,, Special interest groups appear to have ...
(Date:12/17/2009)... Calif., Dec. 17 Abaxis, Inc. (Nasdaq: ... point-of-care blood analysis instruments and rapid tests for ... that it has entered the production animal diagnostics ... Influenza Antigen Test. This is a USDA-licensed test ... chickens, turkeys and ducks. The disposable, non-instrumented device, ...
(Date:12/17/2009)... LONDON, December 17 Researchers from the ... Loughborough University in the UK are today,encouraging ... in the,New Year following concerning research* that shows ... together as a family (68%), with the,Portuguese being ... likely to,walk together. , ...
(Date:12/17/2009)... functions were determining factors. StaffKnex, developers of web-based nurse ... selected by Lifespace Communities to deliver its software solution ... ... Cleveland, OH (PRWEB) December 17, ... nurse scheduling and employee communication software, recently announced it ...
(Date:12/17/2009)... engines like Google Local and in front of their local customers ... Registration service offered by New Orleans based Webtyde Internet Marketing. ... ... In order to be competitive locally and nationally, businesses must have ... local map section in a major search engine, a business must ...
Breaking Medicine News(10 mins):Health News:Special Interest Deceptions Continue to Rampant About Electronic Cigarettes 2Health News:ABAXIS(R) Announces Exclusive Worldwide OEM Agreement for a Lateral Flow Avian Influenza Antigen Test Kit 2Health News:ABAXIS(R) Announces Exclusive Worldwide OEM Agreement for a Lateral Flow Avian Influenza Antigen Test Kit 3Health News:ABAXIS(R) Announces Exclusive Worldwide OEM Agreement for a Lateral Flow Avian Influenza Antigen Test Kit 4Health News:The Family Walk - a Dying Tradition Around the World? 2Health News:Lifespace Communities Selects StaffKnex Software for Nurse Scheduling and Employee Communications 2Health News:Lifespace Communities Selects StaffKnex Software for Nurse Scheduling and Employee Communications 3Health News:New Orleans Based Internet Marketing Is Helping Small Businesses Get a Chance to Shine On the Web 2
... that evening administration of the central alpha(2)-agonists guanabenz ... the morning in hypertensive patients. The study was ... receive once-daily evening administration of guanabenz or clonidine ... of the two drugs in the morning and ...
... lifestyle with limiting TV time could prevent obesity and type ... watching results in a lower metabolic rate when compared to ... a car. Prolonged TV watching is also linked to obesity ... and hardly concentrate on reducing sedentary behaviours.// ...
... that treatment with adult stem cells has cured mice ... have recovered completely from paralysis of their back legs, ... with stem cells extracted from the brains of adult ... showed that the stem cells had migrated to and ...
... in Journal of the American College of Cardiology suggests ... profile for the heart when delivered through a patch ... the largest study of its kind, was cut short ... Replacement Therapy (a combination of estrogen and progestin) increased ...
... glucose levels are above normal. People with diabetes have ... into a sugar called glucose, which is carried by ... the hormone insulin, made in the pancreas, to help ... can prevent or delay complications by keeping blood glucose ...
... discuss with their physicians, can be an early warning ... disease, hypertension, diabetes, high cholesterol, obesity and smoking are ... estimated that Erectile dysfunction affects 40 million men, yet ... tell and doctors never ask.// ED is one symptom ...
Other Medicine News:
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: